DEST — Destiny Pharma Income Statement
0.000.00%
Last trade - 00:00
- £15.49m
- £5.65m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6.08 | 5.58 | 6.55 | 6.29 | 7.78 |
Operating Profit | -6.08 | -5.58 | -6.55 | -6.29 | -7.78 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -6.01 | -5.52 | -6.48 | -6.27 | -7.71 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.17 | -4.71 | -5.41 | -5.34 | -6.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.17 | -4.71 | -5.41 | -5.34 | -6.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.17 | -4.71 | -5.41 | -5.34 | -6.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.118 | -0.107 | -0.12 | -0.089 | -0.093 |